[{"orgOrder":0,"company":"Cynata Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Podiatry","country":"","productType":"Cell and Gene therapy","year":"2021","type":"Not Applicable","leadProduct":"Cymerus mesenchymal stem cell","moa":"","graph1":"Podiatry","graph2":"Preclinical","graph3":"Cynata Therapeutics","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Podiatry","amount2New":0,"dosageForm":"","sponsorNew":"Cynata Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"4","companyTruncated":"Cynata Therapeutics \/ Not Applicable"},{"orgOrder":0,"company":"Cynata Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Podiatry","country":"","productType":"Cell and Gene therapy","year":"2021","type":"Not Applicable","leadProduct":"Cymerus mesenchymal stem cells","moa":"","graph1":"Podiatry","graph2":"Preclinical","graph3":"Cynata Therapeutics","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Podiatry","amount2New":0,"dosageForm":"","sponsorNew":"Cynata Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"4","companyTruncated":"Cynata Therapeutics \/ Not Applicable"},{"orgOrder":0,"company":"MiMedx","sponsor":"MediWound","pharmaFlowCategory":"D","therapeuticArea":"Podiatry","country":"","productType":"Large molecule","year":"2023","type":"Collaboration","leadProduct":"Bromelain Enriched Proteolytic Enzyme","moa":"","graph1":"Podiatry","graph2":"Preclinical","graph3":"MiMedx","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Podiatry","amount2New":0,"dosageForm":"Gel","sponsorNew":"MiMedx \/ MediWound","highestDevelopmentStatusID":"4","companyTruncated":"MiMedx \/ MediWound"},{"orgOrder":0,"company":"Innocan Pharma","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Podiatry","country":"","productType":"Small molecule","year":"2023","type":"Not Applicable","leadProduct":"Cannabidiol","moa":"","graph1":"Podiatry","graph2":"Preclinical","graph3":"Innocan Pharma","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Podiatry","amount2New":0,"dosageForm":"Cream","sponsorNew":"Innocan Pharma \/ Not Applicable","highestDevelopmentStatusID":"4","companyTruncated":"Innocan Pharma \/ Not Applicable"}]

Find Clinical Drug Development Pipelines & Deals | PipelineProspector

Xls
Filters Filter
×
FILTER:
filter
Company Name
    filter

    Year

      filter

      DEALS // DEV.

        filter

        Country

          filter
          Sponsor
            filter

            Therapeutic Area

              filter

              Study Phase

                filter

                Deal Type

                  filter

                  Product Type

                    filter

                    Dosage Form

                      filter

                      Lead Product

                        filter

                        Target

                          Loading...

                          Therapeutic Area by Lead Product

                          Study Phase by Lead Product

                          Company by Lead Product

                          Top Deals by Deal Size (USD bn)

                          01

                          2024 ACI Convention
                          Not Confirmed
                          2024 ACI Convention
                          Not Confirmed

                          Details : The collaboration aims to develop and manufacture FibroBiologics’ therapeutic master cell bank, working cell bank, and fibroblast-based spheroids product, CYWC628, for diabetic foot ulcer (DFU).

                          Brand Name : CYWC628

                          Molecule Type : Cell and Gene therapy

                          Upfront Cash : Undisclosed

                          October 18, 2024

                          Lead Product(s) : CYWC628

                          Therapeutic Area : Podiatry

                          Highest Development Status : Preclinical

                          Sponsor : FibroBiologics

                          Deal Size : Undisclosed

                          Deal Type : Collaboration

                          blank

                          02

                          2024 ACI Convention
                          Not Confirmed
                          2024 ACI Convention
                          Not Confirmed

                          Lead Product(s) : Bromelain Enriched Proteolytic Enzyme,Dehydrated Human Amnion Membrane

                          Therapeutic Area : Podiatry

                          Study Phase : Preclinical

                          Sponsor : MediWound

                          Deal Size : Undisclosed

                          Deal Type : Collaboration

                          Details : Under the collaboration, MIMEDX will provide its market leading placental tissue allograft EPIFIX® to be used during the wound healing phase of the EscharEx® (concentrate of proteolytic enzymes enriched in bromelain) Phase III study in venous leg ulcer...

                          Brand Name : EscharEx

                          Molecule Type : Large molecule

                          Upfront Cash : Undisclosed

                          August 15, 2023

                          Lead Product(s) : Bromelain Enriched Proteolytic Enzyme,Dehydrated Human Amnion Membrane

                          Therapeutic Area : Podiatry

                          Highest Development Status : Preclinical

                          Sponsor : MediWound

                          Deal Size : Undisclosed

                          Deal Type : Collaboration

                          blank

                          03

                          2024 ACI Convention
                          Not Confirmed
                          2024 ACI Convention
                          Not Confirmed

                          Details : Cannabidiol is a topical CB1 receptor negative allosteric modulator (NAM), which is being evaluated in phase 1 clinical studies for the treatment of Diabetic Foot.

                          Brand Name : Undisclosed

                          Molecule Type : Small molecule

                          Upfront Cash : Not Applicable

                          August 15, 2023

                          Lead Product(s) : Cannabidiol

                          Therapeutic Area : Podiatry

                          Highest Development Status : Preclinical

                          Sponsor : Not Applicable

                          Deal Size : Not Applicable

                          Deal Type : Not Applicable

                          blank

                          04

                          2024 ACI Convention
                          Not Confirmed
                          2024 ACI Convention
                          Not Confirmed

                          Details : This will be the first clinical trial to utilise CYP-006TK, a polymer-coated silicon dressing (seeded with Cymerus MSCs) that Cynata has licensed from TekCyte Pty Ltd (TekCyte).

                          Brand Name : CYP-006TK

                          Molecule Type : Cell and Gene therapy

                          Upfront Cash : Not Applicable

                          June 30, 2021

                          Lead Product(s) : Cymerus mesenchymal stem cells

                          Therapeutic Area : Podiatry

                          Highest Development Status : Preclinical

                          Sponsor : Not Applicable

                          Deal Size : Not Applicable

                          Deal Type : Not Applicable

                          blank

                          05

                          2024 ACI Convention
                          Not Confirmed
                          2024 ACI Convention
                          Not Confirmed

                          Details : Cynata plans to undertake a clinical trial of its Cymerus MSC product in patients with diabetic foot ulcers based on this solid pre-clinical foundation and utilising the TekCyte technology.

                          Brand Name : Undisclosed

                          Molecule Type : Cell and Gene therapy

                          Upfront Cash : Not Applicable

                          March 01, 2021

                          Lead Product(s) : Cymerus mesenchymal stem cell

                          Therapeutic Area : Podiatry

                          Highest Development Status : Preclinical

                          Sponsor : Not Applicable

                          Deal Size : Not Applicable

                          Deal Type : Not Applicable

                          blank